NewGenIvf Group (NASDAQ:NIVF) Cut to “Strong Sell” at Wall Street Zen

Wall Street Zen lowered shares of NewGenIvf Group (NASDAQ:NIVF) to a strong sell rating in a report published on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings reiterated a “sell (d)” rating on shares of NewGenIvf Group in a report on Friday, July 24th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat, the company currently has an average rating of “Sell”.

NewGenIvf Group Trading Down 20.5%

Shares of NIVF stock opened at $1.16 on Friday. NewGenIvf Group has a 1-year low of $1.14 and a 1-year high of $21,425.47. The firm’s 50-day simple moving average is $23.82 and its 200-day simple moving average is $463.22.

NewGenIvf Group (NASDAQ:NIVF) last issued its earnings results on Wednesday, October 7th. The company reported ($426.24) earnings per share for the quarter, missing analysts’ consensus estimates of $581.76 by ($1,008.00). The company had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $20.10 million. On average, equities research analysts forecast that NewGenIvf Group will post 1365.44 EPS for the current year.

About NewGenIvf Group

NewGenIvf Group Limited is a reproductive-healthcare company focused on fertility treatment and assisted reproductive technology. Through its operating businesses, the company provides services intended to help individuals and couples pursue pregnancy, including in vitro fertilization (IVF) and related fertility-care procedures.

Its services may include fertility consultations, laboratory-based embryo procedures, intracytoplasmic sperm injection (ICSI), embryo transfer, fertility preservation, and genetic testing or screening associated with assisted reproduction.